Ontology highlight
ABSTRACT:
SUBMITTER: Larsen JT
PROVIDER: S-EPMC5507724 | biostudies-literature | 2017 Aug
REPOSITORIES: biostudies-literature
Larsen Jeremy T JT Shanafelt Tait D TD Leis Jose F JF LaPlant Betsy B Call Tim T Pettinger Adam A Hanson Curtis C Erlichman Charles C Habermann Thomas Matthew TM Reeder Craig C Nikcevich Daniel D Bowen Deborah D Conte Michael M Boysen Justin J Secreto Charla C Lesnick Connie C Tschumper Renee R Jelinek Diane D Kay Neil E NE Ding Wei W
American journal of hematology 20170601 8
Akt is a downstream target of B cell receptor signaling and is a central regulator of CLL cell survival. We aim to investigate the safety and efficacy of the Akt inhibitor MK-2206 in combination with bendamustine and rituximab (BR) in relapsed and/or refractory CLL in a phase I/II study. A standard phase I design was used with cohorts of three plus three patients to determine the maximum tolerated dose (MTD) of MK-2206 in combination with BR in relapsed CLL. Single-agent MK-2206 (weekly dosed) w ...[more]